Atlas
Back to Pharma Services
Investment Banker·Pharma Services

Nick Bell

Managing Director, Global Healthcare Investment Banking at Robert W. Baird

Charlotte, North Carolina

NB
Why they matter

He's Baird's dedicated pharma-services banker covering CDMOs, CROs and pharma IT — a natural first call for sell-side or platform M&A intel in the sector.

Background

Nick Bell is a Managing Director in Robert W. Baird's Global Healthcare Investment Banking Group, where since 2021 he has led M&A and capital markets coverage of outsourced pharmaceutical services and technologies — spanning drug discovery, CDMOs, CROs, pharma IT and commercialization. He joined Baird from BlackArch Partners, where he was a Director focused on middle-market M&A for financial sponsors and founder-backed businesses, and earlier served as a Vice President in Wells Fargo Securities' Global M&A group. He holds an MBA with high distinction from the University of Michigan Ross School of Business and a B.S. in Foreign Service from Georgetown University.

Notable deals

  • 2021
    Joined Baird's Global Healthcare Investment Banking team as Director to build out the firm's dedicated pharma services (CDMO/CRO) coverage
  • 2023
    Named Managing Director contact for Baird's Global Pharma Services practice as it closed 18 sell-side and buy-side transactions across CDMOs, CROs and pharma IT over the prior 24 months
  • 2014
    Co-Managing Director of the $6.5 million student-run Wolverine Venture Fund at Michigan Ross, focused on early-stage life sciences and technology investing; received the Gelband and Shelby Awards

Call-prep brief

Background

  • MD in Baird's Global Healthcare Investment Banking Group; joined 2021 specifically to extend Baird's coverage of outsourced pharma services (drug discovery, CDMO, CRO, pharma IT, commercialization).
  • Prior stops: Director at BlackArch Partners (middle-market, sponsor and founder-backed M&A), VP at Wells Fargo Securities Global M&A. Early career in strategy/M&A planning (now part of Oliver Wyman) and at Day & Zimmermann.
  • MBA (High Distinction), University of Michigan Ross, where he co-led the Wolverine Venture Fund investing in early-stage life sciences/tech; BSFS from Georgetown.

Current Focus

  • Sits inside Baird's pharma services franchise, which has been one of the more transaction-active practices in healthcare IB (18 deals in a 24-month stretch cited by the firm in 2023), covering CDMO, CRO, pharma IT and commercialization targets.
  • Works alongside Baird colleagues (e.g., Adam Huitt) on both sell-side auctions and sponsor-backed platform build-ups in the space.

What He Cares About

  • Positioning outsourced pharma services companies for sponsor-to-sponsor or strategic exits; framing growth/margin stories for CDMO and CRO assets amid a crowded, consolidating sector.
  • Deal process credibility — Baird's healthcare franchise markets itself on high transaction velocity and repeat sponsor relationships.

Recent Moves / Sensitivities

  • No public promotion date found for his MD title (bio + press only confirm Director in 2021); worth confirming current seniority/deal-lead status directly rather than assuming.
  • As sell-side/buy-side advisor, he will be guarded about naming specific mandates or non-public processes — expect general market color rather than confirmation of active deals.

Questions to Ask

  1. Which CDMO/CRO subsegments (small-molecule vs. biologics, early discovery vs. commercial-scale manufacturing) are seeing the most sponsor demand and pricing tension right now?
  2. How are recent CDMO/CRO exits (e.g., strategic vs. sponsor-to-sponsor) being valued differently, and what's driving the gap?
  3. What operational or capacity-utilization metrics do buyers scrutinize most closely in current pharma services diligence?

Outreach draft

Subject
Pharma Services M&A — Quick Perspective Call
Hi Nick, I'm [Placeholder Name] with a private equity firm evaluating opportunities in the pharma services / CDMO space. Given your coverage at Baird — from drug discovery through CDMOs, CROs and pharma IT — I'd value your perspective on where sponsor demand and valuations are heading in the sector right now. Would you have 20-30 minutes in the next couple of weeks for a quick call? Happy to work around your schedule, and glad to share what we're seeing on our end as well. Thanks in advance, [Placeholder Name]

Linked companies

Sources